Skip to main content
. 2015 Mar 13;20(1):658–666. doi: 10.2119/molmed.2014.00215

Figure 1.

Figure 1

ARA 290 administration is associated with an improvement in Hb A1c at d 28 and is maintained at least 4 wks following dosing. The A1c percentage decreased significantly from baseline in the group receiving ARA 290 (4 mg SC daily for 28 d; filled circles), whereas the placebo group (open circles) remained unchanged. Follow-up at an additional 28 d showed the ARA 290 treatment group maintained an improved A1c profile (p = 0.002; repeated measures ANOVA).

HHS Vulnerability Disclosure